Novogen Announces Preclinical Studies Justifies Mode Of Delivery And Dosing Regimen For Anisina
US-Australian drug discovery company, Novogen Limited (NASDAQ: NVGN), today announced details of preclinical studies which confirm the efficacy of the lead anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration and dosing regimen.
Presenting at the ‘American Association for Cancer Research Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship' conference in Fort Lauderdale, Florida today, Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said "These data validate the strategic decision to develop the Anisina drug candidate. We have shown that intravenously administered Anisina dosed less frequently in a preclinical study retained anti-cancer activity as a monotherapy, and enhanced the efficacy of a drug commonly used to treat pediatric neuroblastoma".
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.